The abstract is read at the publisher; the summary is JClub's.
Osteoblast GPAT2 is linked to impaired phosphate incorporation in CKD, with elevated GPAT2 shifting fatty acids toward lysophosphatidic acid and higher FGF23.
- Why it matters: CKD causes both defective skeletal mineralization and cardiovascular pathology, but the mechanism connecting phosphate imbalance to systemic disease is unclear.
- What they did: In mouse and human CKD, the study tested osteoblast GPAT2 function using osteoblast-specific Gpat2 deletion and a bone-targeted GPAT inhibitor, tracking FFA routing, phosphate, FGF23, and vascular and cardiac outcomes.
- The result: Osteoblast-specific Gpat2 deletion and bone-targeted GPAT inhibition restored osteoblast fatty acid oxidation, reduced circulating phosphate and FGF23, and attenuated vascular calcification and cardiac hypertrophy in CKD models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.